<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00554151</url>
  </required_header>
  <id_info>
    <org_study_id>MAARS CIP Version 5</org_study_id>
    <nct_id>NCT00554151</nct_id>
  </id_info>
  <brief_title>Mitral Adjustable Annuloplasty Ring Feasibility and Safety Study</brief_title>
  <acronym>MAARS</acronym>
  <official_title>Mitral Adjustable Annuloplasty Ring Feasibility and Safety Study (MAARS) for Treatment of Patients With Mitral Valve Regurgitation in Open Surgical Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the technical feasibility and safety of the Mitral Adjustable Annuloplasty&#xD;
      Ring.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Establish the technical feasibility and safety of implantation of the investigation device,&#xD;
      adjustment of the investigational device post-implantation, and the ability of the&#xD;
      investigational device to reduce mitral valve regurgitation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Freedom from major adverse events (MAE)at 30 days. Performance: Technical success rate of implantation of the investigation device.</measure>
    <time_frame>30 days, 90 days, 6 months and 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ability to adjust the investigational device post-ring implantation after the patient has been weaned from CPB. MR reduction to &lt;2+ post procedure, at post operative hospital discharge, at 30 days, at 6 months and one year.</measure>
    <time_frame>30 days, 90 days, 6 months and 1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Mitral Valve Regurgitation</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Adjustable Annuloplasty Ring</intervention_name>
    <description>The investigational device is intended for use in the treatment of mitral valve regurgitation.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females aged greater or equal to 18 to less than or equal to age 75.&#xD;
&#xD;
          -  Patients with indications to undergo mitral valve repair consistent with ACC/AHA&#xD;
             recommendations; including greater or equal to 2+ regurgitation by pre-operative TEE&#xD;
             or TTE assessment.&#xD;
&#xD;
          -  Candidate for cardiopulmonary bypass.&#xD;
&#xD;
          -  A Left Ventricular Ejection Fraction greater or equal to 40%.&#xD;
&#xD;
          -  Able and willing to comply with all study requirements, including the required study&#xD;
             follow-up visits.&#xD;
&#xD;
          -  Able and willing to five consent and follow study instructions.&#xD;
&#xD;
          -  Female patients of childbearing potential (not surgically sterilized or more than one&#xD;
             year postmenopausal), with a negative pregnancy test (serum beta-hCG) within 24 hours&#xD;
             prior to mitral valve surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any previous cardiac surgery.&#xD;
&#xD;
          -  Any interventional cardiology procedure within six months prior to study to include&#xD;
             all patients that have had a drug eluting stent (DES) implanted within 6 months.&#xD;
&#xD;
          -  Evidence of an acute Myocardial Infarction (MI) within 7 days of the intended&#xD;
             treatment with the investigational device.&#xD;
&#xD;
          -  Prior mitral valve surgery or valvuloplasty or currently implanted prosthetic valve.&#xD;
&#xD;
          -  Restricted mobility of the mitral apparatus that results in a valvular area less than&#xD;
             3.0 cm2.&#xD;
&#xD;
          -  Recent or evolving bacterial endocarditis or patients under current antibiotic&#xD;
             therapy.&#xD;
&#xD;
          -  Patients with ICD's.&#xD;
&#xD;
          -  Any angiographic or clinical evidence that the investigator feels would place the&#xD;
             patient at increased risk with the placement of the device or concurrent medical&#xD;
             condition with a life expectancy of less than 12 months.&#xD;
&#xD;
          -  Patients who are immunocompromised or with autoimmune diseases.&#xD;
&#xD;
          -  Patients suffering from renal insufficiency (Creatinine &gt;2.5 mg/dL) or patients with&#xD;
             chronic renal failure undergoing dialysis.&#xD;
&#xD;
          -  Co-morbid conditions that place the subject at an unacceptable surgical risk (e.g.&#xD;
             sever chronic obstructive pulmonary disease, hepatic failure, immunosuppressive&#xD;
             abnormalities, haematological abnormalities).&#xD;
&#xD;
          -  Significant mitral annular calcification.&#xD;
&#xD;
          -  Use of Coumadin, IIbIIIa inhibitors, Clopidigrel (Plavix) or other anti-coagulants&#xD;
             within (5) five days prior to surgery.&#xD;
&#xD;
          -  Participation in any study involving an investigational drug or device within the past&#xD;
             month, or ongoing participation in a study with an investigational device.&#xD;
&#xD;
          -  Intolerance or hypersensitivity to anaesthetics.&#xD;
&#xD;
          -  Patients in whom transesophageal echo/Doppler is contraindicated.&#xD;
&#xD;
          -  History of bleeding diathesis or coagulopathy.&#xD;
&#xD;
          -  History of stroke within the prior 6 months&#xD;
&#xD;
          -  Subjects to undergo concomitant cardiac repair or replacement other than CABG (less&#xD;
             than or equal to 3 vessels) mitral annuloplasty, tricuspid valve repair and ablation&#xD;
             therapy for correction of atrial fibrillation. Excluded concomitant procedures are:&#xD;
             aortic valve replacement, LV remodeling, surgery and congenital repair.&#xD;
&#xD;
          -  Patients with Euroscore &gt; 10.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Franka Borger, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Leipzig Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A.P. Kappetein, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC, Universitair Medisch Centrum Rotterdam</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R.J.M. Klautz, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leids Universitair Medisch Centrum Lieden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anno Diegeler, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herz-und Gefäß-Klinik GmbH Bad Neustadt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ottavio Alfieri, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Rafaele</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herz - und Gefäß-Klinik GmbH Bad Neustadt</name>
      <address>
        <city>Bad Neustadt</city>
        <state>Saale</state>
        <zip>97615</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC, Universitair Medisch Centrum Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>November 2, 2007</study_first_submitted>
  <study_first_submitted_qc>November 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2007</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <name_title>Vicki Bebeau</name_title>
    <organization>St. Jude Medical, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

